Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Genentech Showcases New Clinical Data across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
November 3, 2016 12:30 PM EDTNew results from the Phase III GALLIUM study which compared Gazyva® (obinutuzumab) plus chemotherapy to Rituxan® (rituximab) plus chemotherapy in previously untreated follicular lymphoma will be presented in the Plenary Scientific Session New results for Venclexta (venetoclax) and investigational medicine emicizumab will also be presented at the meeting FDA has accepted the Biologics License Application for a subcutaneous formulation of Rituxan® (rituximab/hyaluronidase)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:... More
Rogers Corporation Reports Results for the 2016 Third Quarter
November 2, 2016 4:23 PM EDTNet sales of $165.3 million, up 3.1% Gross margin of 37.5%, up 30 basis points Net income of $16.1 million, up 28.1% Adjusted EBITDA of $34.1 million, 20.6% of net sales
ROGERS, Conn.--(BUSINESS WIRE)-- Rogers Corporation (NYSE: ROG) today announced financial results for the 2016 third... More
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
November 2, 2016 1:00 AM EDT15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra data from GiACTA - the largest ever clinical trial in people with giant cell arteritis (GCA), a condition for which there has been no approved therapy in more than 50 years New data from two studies investigating cardiovascular outcomes for people with rheumatoid arthritis (RA) treated with Actemra
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),... More
